triacsin C

from Streptomyces No. 1228; structure given in first source; an acyl-CoA synthetase antagonist

Also Known As:

1-hydroxy-3-(2',4',7'-undecatrienylidine)triazene; WS 1228A; WS-1228A; 2,4,7-Undecatrienal, nitrosohydrazone, (E,E,E)-

Networked: 16 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Triazenes: 36
  - triacsin C: 16

Experts

1.	Mashima, Tetsuo: 2 articles (08/2009 - 05/2005)
2.	Sato, Shigeo: 2 articles (08/2009 - 05/2005)
3.	Sugimoto, Yoshikazu: 2 articles (08/2009 - 05/2005)
4.	Tsuruo, Takashi: 2 articles (08/2009 - 05/2005)
5.	Basler, Christopher F: 1 article (07/2020)
6.	Chvatal, Stacie A: 1 article (07/2020)
7.	Jureka, Alexander S: 1 article (07/2020)
8.	Nicolini, Anthony M: 1 article (07/2020)
9.	Silvas, Jesus A: 1 article (07/2020)
10.	Alberici, Luciane C: 1 article (10/2017)

Related Diseases

1.	Infections 04/15/2014 - "The findings of this study not only validated Cryptosporidium ACS (and related acyl-[acyl-carrier-protein]-ligases) as pharmacological targets but also indicate that triacsin C and analogues can be explored as potential new therapeutics against the virtually untreatable cryptosporidial infection in immunocompromised patients." 08/01/2014 - "Here, we examine the effect on productive infection of triacsin C and YIC-C8-434, which inhibit synthesis of TAGs and CEs by targeting long-chain acyl-CoA synthetase and acyl-CoA:cholesterol acyltransferase, respectively. "
2.	Neoplasms (Cancer) 01/01/2008 - "FACL4 selective inhibitor triacsin C leads to a marked growth inhibition of human liver tumor cells, based on the inhibition of proliferation and induction of apoptosis. " 05/18/2005 - "Finally, Triacsin c suppressed growth of xenograft tumors (relative tumor volume on day 21 of Triacsin c-treated versus untreated mice; means = 4.6 and 9.6, respectively; difference = 5.0, 95% CI = 2.1 to 7.9; P = .006). " 05/18/2005 - "Nude mice carrying NCI-H23 xenograft tumors (n = 10) were treated with Triacsin c or vehicle, and xenograft tumor growth was assessed. " 05/18/2005 - "Triacsin c selectively induced apoptosome-mediated death in tumor cells (caspase activity of Triacsin c-treated versus untreated SF268 cells; means = 1020% and 100%, respectively; difference = 920%, 95% CI = 900% to 940%; P<.001). "
3.	Colonic Neoplasms (Colon Cancer) 10/10/2000 - "Exogenous arachidonic acid caused apoptosis in colon cancer and other cell lines, as did triacsin C, a FACL inhibitor. " 05/18/2005 - "We compared cell death, cytochrome c release, and caspase activation in NCI-H23 (lung cancer), HCT-15 (colon cancer), and SF268 (brain cancer) cells treated with Triacsin c, an inhibitor of acyl-CoA synthetase (ACS), or with vehicle. "
4.	Non-alcoholic Fatty Liver Disease 10/01/2017 - "Therefore, triacsin C at sub-IC50 concentrations modulates the lipid imbalance by shifting hepatocytes to a more oxidative state and enhancing the fatty acid consumption, which can in turn accelerate lipid oxidation and reverse NAFLD in long-term therapies."
5.	Parkinsonian Disorders (Parkinsonism) 01/01/2023 - "Knockdown of ACSL4 in the SN protected against dopaminergic neuronal death and motor deficits in the MPTP mice, while inhibition of ACSL4 activity with Triacsin C similarly ameliorated the parkinsonism phenotypes. "

Related Drugs and Biologics

1.	Ligases (Synthetase)
2.	Acyl Carrier Protein
3.	Fatty Acids (Saturated Fatty Acids)
4.	Acyl Coenzyme A (Acyl CoA)
5.	Apoptosomes (Apoptosome)
6.	Cytochromes c (Cytochrome c)
7.	Caspases
8.	Phosphatidylinositol 3-Kinases (PI 3 Kinase)
9.	Nitric Oxide Synthase (NO Synthase)
10.	Arachidonic Acid (Vitamin F)

Related Therapies and Procedures

1.	Therapeutics